Mateon Provides Corporate Update and Reports First Quarter 2017 Financial Results
08 mai 2017 16h15 HE
|
Mateon Therapeutics
SOUTH SAN FRANCISCO, Calif., May 08, 2017 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (OTCQX:MATN), a biopharmaceutical company developing vascular disrupting agents (VDAs) for the treatment of...
Mateon Therapeutics Announces Presentations at the Tumor Microenvironment Workshop
27 avr. 2017 09h15 HE
|
Mateon Therapeutics
SOUTH SAN FRANCISCO, Calif., April 27, 2017 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (OTCQX:MATN), a biopharmaceutical company developing vascular disrupting agents (VDAs) for the treatment of...
Mateon Announces Initiation of Investigator-Sponsored Phase 1 Study of CA4P in Combination with Everolimus in Neuroendocrine Tumors
20 avr. 2017 08h05 HE
|
Mateon Therapeutics
SOUTH SAN FRANCISCO, Calif., April 20, 2017 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (OTCQX:MATN), a biopharmaceutical company developing vascular disrupting agents (VDAs) for the treatment of...
Mateon Therapeutics Announces Encouraging Results from First Interim Analysis of Phase 2/3 FOCUS Study in Platinum-resistant Ovarian Cancer
18 avr. 2017 07h55 HE
|
Mateon Therapeutics
No Significant CA4P Drug Safety Issues IdentifiedInitial Efficacy in Favor of CA4P, with 22% of CA4P Patients Responding versus 9% in the Control ArmEnrollment in the Study Continuing SOUTH SAN...
Mateon Therapeutics Announces Abstract Presentations for the American Association for Cancer Research Annual Meeting in April 2017
31 mars 2017 09h05 HE
|
Mateon Therapeutics
SOUTH SAN FRANCISCO, Calif., March 31, 2017 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (OTCQX:MATN), a biopharmaceutical company developing vascular disrupting agents (VDAs) for the treatment of...
Mateon Therapeutics Reviews 2016 Highlights and Reports 2016 Financial Results
30 mars 2017 08h30 HE
|
Mateon Therapeutics
SOUTH SAN FRANCISCO, Calif., March 30, 2017 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (OTCQX:MATN), a biopharmaceutical company developing vascular disrupting agents (VDAs) for the treatment of...
Mateon Therapeutics Announces Initial Data from Third Cohort of Phase 1b Study of OXi4503 in Relapsed/Refractory AML
15 mars 2017 08h00 HE
|
Mateon Therapeutics
One patient of four (25%) achieved a complete remissionNo dose-limiting toxicities observed and study is progressing into the fourth dose cohort SOUTH SAN FRANCISCO, Calif., March 15, 2017 (GLOBE...
Mateon Therapeutics to Present at 29th Annual ROTH Conference
08 mars 2017 09h00 HE
|
Mateon Therapeutics
SOUTH SAN FRANCISCO, Calif., March 08, 2017 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (OTCQX:MATN), a biopharmaceutical company developing vascular disrupting agents (VDAs) for the treatment of...
Mateon Therapeutics Announces Initial Pre-clinical Data on Combination of CA4P with Checkpoint Inhibitors
13 févr. 2017 08h00 HE
|
Mateon Therapeutics
In one study most animals receiving the combination of CA4P and anti-CTLA4 antibody were tumor free at completionThree additional studies provide evidence that CA4P may enhance anti-CTLA4, anti-PD1,...
Mateon Therapeutics to Present at BIO CEO & Investor Conference on February 13, 2017
07 févr. 2017 16h30 HE
|
Mateon Therapeutics
SOUTH SAN FRANCISCO, Calif., Feb. 07, 2017 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (OTCQX:MATN), a biopharmaceutical company developing vascular disrupting agents (VDAs) for the treatment of...